Francis Crick Institute
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
New Lung Cancer Evolution, Treatment Response Patterns Emerge From TRACERx Study
TRACERx researchers reported on non-small cell lung cancer features linked to disease progression, recurrence, treatment response, and more in seven new papers.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
Cancer Genome Analysis Points to Biallelic Mutations to Inform Variant Interpretation
Investigators saw mutations affecting both maternal and paternal alleles in 21 percent of tumors in a pan-cancer collection, including mutations reflecting a tumor's mutagenic history.
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).